NEWS

OUR DEALS IN THE NEWS

July 12, 2019 – STAATZ BD&S acted as strategic and operational business development advisor to BliNK Biomedical during the negotiation of a Commercial License Agreement with Genmab A/S. Genmab will use their DuoBody technology and a CD47 antibody from BliNK Biomedical to develop the CD47 target with a bispecific approach. BliNK Biomedical will receive an upfront payments of USD 2.25 million and is eligible to receive up to approximately USD 200 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.

Press release: https://ir.genmab.com/news-releases/news-release-details/genmab-and-blink-biomedical-enter-commercial-license-agreement.

 

June 4, 2018 ─ Staatz acted as strategic and operational business development advisor to a privately held French biotechnology client for a contract with a private US biotechnology company regarding an asset purchase agreement for a family of proprietary pre-clinical stage antibodies which are designed for application in various tumor and other indication areas.

 

June 1, 2018 ─ Staatz acted as strategic and operational business development advisor to a French biotechnology client for a contract with a mid-size public European biotechnology company regarding a global, exclusive research collaboration and commercial license option agreement on bispecific antibodies for tumor indications.

 

October 10, 2017 ─ Staatz Business Development & Strategy acted as transaction advisor to GamaMabs Pharma, a France-based immuno-oncology biotechnology Company, in a licensing agreement with Medimmune, the global biologics research and development arm of AstraZeneca, to develop an antibody drug conjugate (ADC) to treat cancer:

MedImmune and GamaMabs Enter Licensing Agreement to Develop Antibody Drug Conjugate Targeting Cancer

 

May 8, 2017 ─ Staatz acted as business development advisor to Luxendo, a spin-off of the European Molecular Biology Laboratory (EMBL), regarding its all share sale to Bruker Corp., USA:

LSP portfolio company Luxendo acquired by Bruker: successful exit after 1,5 years validates LSP’s investment rationale

EMBL Ventures portfolio company Luxendo acquired by Bruker: successful exit... 

 

March 31, 2017 ─ Our team advised Swiss-based Calypso Biotech in its global licensing and collaboration agreement with EA Pharma, Japan:

Calypso Biotech SA entered a global licensing and collaboration agreement with EA Pharma: exclusive worldwide license for the development, manufacturing and marketing of CALY-001  

 

March 16, 2017 ─ Staatz acted as strategic and operational business development advisor to its US biotechnology client regarding a research collaboration and option agreement with a US-based mid-size biotechnology company for a global, exclusive license on a targeted CAR cell therapy product.